Amicus Therapeutics (FOLD 1.79%) saw its excellent 2012 performance cut in half today, as shares that had been up 70% for the year fell 45% in a single day. The fall came on news that the company's lead drug, called migalastat, which was designed to treat Fabry disease, failed to meet its primary endpoint in its phase 3 trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn break down this news, and discuss where Amicus and GlaxoSmithKline (GSK 1.15%), with whom Amicus was partnered on the compound, can go from here.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.